LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Puma Biotechnology Inc

Puma Biotechnology Inc

Chiusa

SettoreSettore sanitario

6.93 -2.81

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.88

Massimo

6.95

Metriche Chiave
By Trading Economics
Entrata	-16M -3.8M
Vendite	-31M 45M
P/E Media del settore	14.875 51.415
EPS	-0.04
Margine di Profitto	-8.377
Dipendenti	179
EBITDA	-28M -1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-27.75% downside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-20M 363M
Apertura precedente	9.74
Chiusura precedente	6.93

Notizie sul Sentiment di mercato

By Acuity

30%

70%

55 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

3.07 / 3.075 Supporto e resistenza

Puma Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 mag 2026, 23:53 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mag 2026, 23:50 UTC

Discorsi di Mercato

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mag 2026, 23:36 UTC

Discorsi di Mercato

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mag 2026, 23:07 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 mag 2026, 23:05 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mag 2026, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mag 2026, 15:26 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mag 2026, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Puma Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

-27.75% in calo

Previsioni per 12 mesi

Media 5 USD -27.75%

Alto 5 USD

Basso 5 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Puma Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Puma Biotechnology Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

3.07 / 3.075Supporto e resistenza

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

55 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.